WCA 2016 – Scientific Program Saturday March 12, 2016
Saturday March 12 | Room A Room B Room C 14.30 ACOS Symposium Chairs: Stefano Centanni, Joan Soriano Marc Miravitlles “ACOS-The Spanish document”Vito Brusasco “Do we need ACOS?” Mar Fernandez- Nieto “Eosinophilic bronchitis” SEPAR Symposium Chairs: Inmaculada Alfageme, Carlos MeleroAntolín Lopez-Viña“Novedades terapeuticas de la guia española para el manejo del asma GEMA 4.0”Eva Martinez Moragon“Asma y embarazo: dos escenarios para […]
Budesonide and fluticasone propionate differentially affect the airway epithelial barrier
Research I. H. Heijink123*, M. R. Jonker1, M. de Vries13, A. J. M. van Oosterhout13, E. Telenga23, N. H. T. ten Hacken23, D. S. Postma23 and M. van den Berge23 Respiratory Research 2016, 17:2 doi:10.1186/s12931-015-0318-z Abstract Background COPD patients have a higher risk of pneumonia when treated with fluticasone propionate (FP) than with placebo, and a lower risk with budesonide (BUD). We hypothesized that BUD and […]
The geriatric asthma: pitfalls and challenges
Asthma Research and Practice2016 2:2 DOI: 10.1186/s40733-015-0018-y Alida Benfante and Nicola Scichilone Abstract Historically, asthma has been envisioned as a disease of younger ages. This has led to the assumption that respiratory symptoms suggestive of asthma occurring in older ages are to be attributed to conditions other than asthma, mainly COPD. Old observational reports and new epidemiological studies confirm that […]
Higher serum levels of periostin and the risk of exacerbations in moderate asthmatics
Asthma Research and Practice 2016 2:1 DOI: 10.1186/s40733-015-0019-x Abstract Background In asthma, exacerbations and poor disease control are linked to airway allergic inflammation. Serum periostin has been proposed as a systemic biomarker of eosinophilic inflammation. This pilot study aims at evaluating whether in patients with moderate asthma, higher baseline levels of serum periostin are associated with a greater […]
Investigation of occupational asthma: Do clinicians fail to identify relevant occupational exposures?
November/December 2015, Volume 22 Issue 6: 341-347 C de Olim | D Bégin | L-P Boulet | A Cartier | M Gérin | C Lemière BACKGROUND: Specific inhalation challenges (SIC) enable the identification of the agent responsible of occupational asthma (OA). A clinician may fail to identify a specific agent in the workplace, which may potentially lead to a misdiagnosis. The […]
Inflammation Markers and FEF25-75: A Relevant Link in Children With Asthma
Letter to the Editors Open Access Allergy Asthma Immunol Res. 2016 Jan;8(1):84-85. English. http://dx.doi.org/10.4168/aair.2016.8.1.84 Maria Angela Tosca,1 Michela Silvestri,1 Nicoletta Solari,1 Giovanni Arturo Rossi,1 and Giorgio Ciprandi2 Jang and colleagues investigated the relationship between exhaled nitric oxide (FeNO) and atopy profiles in children with asthma.1 They focused their attention mainly on the FeNO, showing that this parameter varied according to the profile […]
The WEB-based Asthma Control: an intriguing connection or a dangerous hazard?
REVIEW Carlo Lombardi, Giovanni Passalacqua and Giorgio Walter Canonica Asthma Research and Practice 201 51:15 DOI: 10.1186/s40733-015-0017-z Abstract Globally, an estimated 300 million people have asthma, presenting a considerable and increasing burden of disease for healthcare systems, families, and patients themselves. Despite two decades of guidelines, asthma seems to remain not optimally controlled in a substantial proportion of people. The achievement of asthma […]
The WCA-2016 Board wishes you Happy Holidays and a productive & prosperous New Year!
Isocyanate exposure and asthma in the UK vehicle repair industry
Occup Med (Lond) (2015) 65 (9):713-718. S. J. Stocks1, K. Jones2, M. Piney3 and R. M. Agius41 NIHR Greater Manchester Primary Care Patient Safety Translational Research Centre, Centre for Primary Care, Institute of Population Health, University of Manchester, Manchester M13 9PL, UK, 2 Health & Safety Laboratory, Buxton, Derbyshire SK17 9JN, UK,3 Health & Safety Executive, Bootle, Merseyside L20 7HS, UK, 4 Centre for Occupational and Environmental Health, Centre for Epidemiology, […]
Three-month validation of a turbuhaler electronic monitoring device: implications for asthma clinical trial use
BMJ Open Resp Res 2015;2:e000097 doi:10.1136/bmjresp-2015-000097 Janine Pilcher1,2, Philippa Shirtcliffe1,2, Mitesh Patel2,3, Steve McKinstry2, Terrianne Cripps1,2, Mark Weatherall1,4 and Richard Beasley1,2 Abstract Background Electronic monitoring of inhaled asthma therapy is suggested as the ‘gold standard’ for measuring patterns of medication use in clinical trials. The SmartTurbo (Adherium (NZ) Ltd, Auckland, New Zealand) is an electronic monitor for use with a turbuhaler device (AstraZeneca, UK). […]